Annual revenue went from KRW 63.9 billion in 2022 to KRW 92 billion in 2023 (up 44.0% year on year), KRW 93.7 billion in 2024 (up 1.8%) and KRW 100.4 billion in 2025 (up 7.2%), rising for three consecutive years from 2023 through 2025. Within 2022–2025, 2025 was the largest year and 2022 the smallest.
The company described 2023 as its record performance at the time, citing US sales growth and domestic artificial joint demand. Operating profit was KRW 5.85 billion in 2022, KRW 7.05 billion in 2023 (up 20.7%), KRW 3.89 billion in 2024 (down 44.8%) and KRW 9.12 billion in 2025 (up 134.3%).
The operating margin slid from 9.1% in 2022 to 7.7% in 2023 and 4.2% in 2024 before recovering to 9.1% in 2025. Parent-level net income turned from KRW 5.13 billion in 2023 to a net loss of KRW 1.32 billion in 2024, then returned to a profit of KRW 6.97 billion in 2025.
Net income including non-controlling interests followed the same path. Operating cash flow was KRW 10.6 billion in 2022 and KRW 2.63 billion in 2023, turned negative at -KRW 6.61 billion in 2024, then recovered to KRW 26.5 billion in 2025.
At end-2025, total equity was KRW 89.2 billion, of which KRW 78.4 billion belonged to parent shareholders, and total liabilities were KRW 82.8 billion. On a quarterly basis, operating profit moved from KRW 3.62 billion in Q3 2025 to KRW 3.09 billion in Q4 2025, then fell to KRW 886 million in Q1 2026, the low point.
It then rose to KRW 1.45 billion in Q2 2026 and KRW 1.8 billion in Q3 2026, an increase in two consecutive quarters, yet Q3 2026 was still down 50.3% year on year.
Parent-level net income was KRW 1.44 billion in Q3 2025, KRW 3.87 billion in Q4 2025, KRW 1.28 billion in Q1 2026 and KRW 1.1 billion in Q2 2026, before a parent net loss of KRW 707 million in Q3 2026.
Preliminary first-half 2026 results, announced July 24, 2026, showed revenue of KRW 50.37 billion (up 9.4%), with the company attributing flat operating profit to upfront costs for US product launch preparation and vendor diversification.